Arq Posts Record Q3 Revenue and Net Income, Tightens FY2026 Adjusted EBITDA Guidance

What happened

Arq reported record quarterly revenue of $38.2 million, up 9% year over year, with net income of $2.5 million, marking a swing to profitability. Adjusted EBITDA reached $8.8 million, a 71% increase, representing the tenth consecutive quarter of positive Adjusted EBITDA. Gross margins improved to 39.7%, driven by strong performance in the powdered activated carbon (PAC) business. Management tightened full-year 2026 Adjusted EBITDA guidance to $19-20 million, up from $17-20 million, signaling confidence in continued operational improvement. The results indicate meaningful progress in profitability and margin expansion, though the company remains a small, leveraged player with single-plant concentration.

Implication

The record revenue, positive net income, and strong Adjusted EBITDA growth demonstrate operational improvement, particularly in the legacy PAC segment, which may reduce near-term execution risk. However, the company remains highly leveraged with net debt/EBITDA over 3x and interest coverage below 1x, and the new GAC facility's ramp to nameplate capacity by mid-2026 is still critical for the long-term thesis. The tightened FY2026 Adjusted EBITDA guidance suggests management's confidence, but investors should verify that the margin improvement is sustainable and not a one-off or cyclical benefit. Until GAC contributes meaningfully to revenue and cash flow normalizes, the equity still trades at a rich EV/EBITDA multiple for a small, single-plant specialty chemical company. Therefore, while the risk/reward has improved, it is not yet compelling enough to shift from WAIT to BUY; we maintain a cautious stance and await further evidence of GAC execution and deleveraging.

Thesis delta

The prior WAIT thesis hinged on GAC ramp uncertainty, high leverage, and unproven moat. This quarter's results, with record revenue, positive net income, and strong Adjusted EBITDA growth, partially alleviate near-term profitability concerns and suggest improving operating leverage. However, the core overhangs of single-plant concentration, elevated leverage, and unproven GAC economics remain, so the stance does not shift to BUY; instead, confidence in the WAIT thesis increases modestly.